Meeting
2019 ASCO Annual Meeting
An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.
Authors
Assuntina Gesualda Sacco
University of California San Diego Moores Cancer Center, San Diego, CA
Assuntina Gesualda Sacco , Ruifeng Chen , Debanjali Ghosh , Deborah J.L. Wong , Francis P. Worden , Douglas Adkins , Emily Pittman , Karen Messer , Kathryn A. Gold , Gregory A. Daniels , Paul Swiecicki , Brian Sutton , Amanda Natsuhara , Ezra E.W. Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03082534
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6033)
DOI
10.1200/JCO.2019.37.15_suppl.6033
Abstract #
6033
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Deborah J.L. Wong
Poster
2019 ASCO Annual Meeting
EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.
First Author: Martin David Forster
Poster
2015 ASCO Annual Meeting
KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.
First Author: Steven Francis Powell
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville